Home > Market Research > Drug Delivery > Insulin Delivery Systems Market Analysis (2007-2010)

Table of Contents

Management Report
Published: May 2007
Pages: 105
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 921.05   Buy Now!
Research from: RNCOS
Sector: Drug Delivery

The report “Insulin Delivery Systems Market Analysis (2007-2010)” by RNCOS provides an updated view on the global Insulin delivery industry, examining and giving a detailed analysis of the various devices used for Insulin delivery. It examines the key trends that are governing the market at present and where the insulin market will head in the future. The report also covers a complete analysis of the insulin markets in the countries having the maximum number of diabetic population.

Key Findings

§ The total number of diabetes patients in the world is expected to grow from 246 Million in 2006 to 380 Million by 2025.
§ Growing at a CAGR of 14.09%, global insulin market will reach US$ 14.5 Billion by 2010 from US$ 7.5 Billion in 2005.
§ Over 60% of the insulin sold in 2006 was sold in pen devices.
§ Insulin pen devices dominate the market in Europe and Japan whereas syringes and pumps dominate the US market.
§ Needle-free injectors haven’t created any impact in the insulin delivery market with market share in 2006 as low as 0.6% in US.
§ Inhaled Insulin devices were earlier thought to make a big success, but Pfizer’s Exubera was a big flop in 2006 with estimated revenues of 1/10th as what had been earlier projected.
§ The Insulin market in 2006 was largely dominated by two players, Novo Nordisk of Denmark and Eli Lilly of USA.
§ India and China are emerging as the most potential future markets for insulin delivery devices.

Key Issues and Facts Analyzed

The market research report also addresses the issues and facts that are critical to your business success:

§ Evaluation of past, current and future market trends.
§ Discussion about the modes of insulin delivery.
§ A detailed analysis of the major insulin delivery devices.
§ Analysis of pros and cons of major insulin devices.
§ Scope of the major insulin delivery systems all over the world.
§ Analysis of various challenges and opportunities for the industry.
§ Profile discussion of key players in the sector.

Key Players Analyzed

This section provides the overview, key facts, and financial information of prominent players in the global insulin delivery market like Eli Lilly & Company, Novo Nordisk A/S, Sanofi-Aventis, GlaxoSmithKline, and Amylin Pharmaceuticals, Inc.

Research Methodology Used

Information Sources
Information has been sourced from various sources like books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to access to more than 3000 paid databases.

Analysis Methods
The analysis methods includes the following:
Ratio Analysis, Historical Trend Analysis, Linear Regression Analysis using software tools, Judgmental Forecasting, and Cause and Effect Analysis.

Top of Page

Table of Contents

1. Analyst View
2. Research Overview
3. Diabetes Disease Indicator
4. Diabetes & Obesity
5. Global Market Analysis
5.1 Global Diabetes Drugs Market
5.2 Global Insulin Market
5.2.1 India
5.2.1.1 Prevalence
5.2.1.2 Market Analysis
5.2.2 China
5.2.2.1 Prevalence
5.2.2.2 Market Analysis
5.2.3 US
5.2.3.1 Prevalence
5.2.3.2 Market Analysis
5.2.4 Russia
5.2.4.1 Prevalence
5.2.4.2 Market Analysis
5.2.5 Japan
5.2.5.1 Prevalence
5.2.5.2 Market Analysis
5.2.6 Germany
5.2.6.1 Prevalence
5.2.6.2 Market Analysis
5.2.7 Pakistan
5.2.7.1 Prevalence
5.2.7.2 Market Analysis
5.2.8 Brazil
5.2.8.1 Prevalence
5.2.8.2 Market Analysis
5.2.9 Mexico
5.2.9.1 Prevalence
5.2.10 Egypt
5.2.10.1 Prevalence
6. Insulin Delivery Devices
6.1 Present Devices
6.1.1 Insulin Syringes
6.1.1.1 Mechanism & Technology
6.1.1.2 Market Analysis
6.1.1.3 Pros & Cons
6.1.1.4 Future Outlook (2007-2010)
6.1.1.5 Key Players in Insulin Syringe Market
6.1.2 Insulin Pen Devices
6.1.2.1 Mechanism & Technologies
6.1.2.2 Market Analysis
6.1.2.3 Pros & Cons
6.1.2.4 Future Outlook (2007-2010)
6.1.2.5 Key Players in Pen Devices Market
6.1.3 Insulin Jet Injectors
6.1.3.1 Mechanism & Technologies
6.1.3.2 Market Analysis
6.1.3.3 Pros & Cons
6.1.3.4 Future Outlook (2007-2010)
6.1.3.5 Key Players in Insulin Jet Injector Market
6.1.4 Insulin Pumps
6.1.4.1 Mechanism & Technologies
6.1.4.2 Market Analysis
6.1.4.3 Pros & Cons
6.1.4.4 Future Outlook (2007-2010)
6.1.4.5 Key Players in Insulin Pump Market
6.2 Future Devices
6.2.1 Inhaled Insulin Devices
6.2.1.1 Mechanism & Technologies
6.2.1.2 Market Analysis
6.2.1.3 Pros & Cons
6.2.1.4 Key Players in Inhaled Insulin Market
6.2.2 Other Future Devices
6.2.2.1 Oral Insulin
6.2.2.2 Insulin Patch
6.2.2.3 Implantable Insulin Pump
7. Industry Analysis
7.1 Drivers
7.1.1 Increasing Number of Diabetic Patients
7.1.2 Convenient & Less Painful Modes of Insulin Delivery
7.1.3 Improved Access & Lower Insulin Prices in the Developing World
7.1.4 Early Diagnosis & Increasing Awareness for Treatment
7.1.5 Government Support
7.2 Challenges
7.2.1 High R&D & Production Cost
7.2.2 Long Time to Market
7.2.3 Poverty
7.2.4 Insurance Reimbursement
7.2.5 Traditional Treatments
7.2.6 High Cost of Insulin Inhalers
7.2.7 Rapidly Changing Technology
7.3 Opportunities
7.3.1 US & Developing Countries - Potential Markets for Insulin Syringes
7.3.2 Europe & Japan - Potential Markets for Pen Devices
7.3.3 Oral Insulin for the Developed World
7.3.4 US - Increased Insulin Pumps Sales in Future
7.4 Future Outlook, 2025
7.4.1 Overview of Global Diabetes Drug Market (2007-2012)
8. Key Players
8.1 Eli Lilly & Company
8.2 Novo Nordisk A/S
8.3 Sanofi-Aventis
8.4 GlaxoSmithKline
8.5 Amylin Pharmaceuticals, Inc

List of Figures:

Figure 4-1: Worldwide - Overweight & Obese Population of Age above 15 years (in Billion), 2005, 2007E & 2015E
Figure 5-1: Worldwide - Number of Diabetes Patients (in Million), 2005 & 2006
Figure 5-2: Worldwide - Diabetes Drug Market (in Billion US$), 2005 & 2006
Figure 5-3: Worldwide - Insulin Market (in Billion US$), 2005 & 2006
Figure 5-4: India - Number of Diagnosed Diabetes Patients (in ‘000), 2003-2006E
Figure 5-5: India - Forecast for Number of Diagnosed Diabetes Patients (in ‘000), 2007, 2013, 2019 & 2025
Figure 5-6: India - Insulin Market (in Million US$), 2004-2007E
Figure 5-7: India - Insulin Market Share of Players (%), 2004
Figure 5-8: China - Number of Diagnosed Diabetes Patients (in ‘000), 2003-2006E
Figure 5-9: China - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 5-10: China - Insulin Market (in Million US$), 2006-2009E
Figure 5-11: China - Insulin Market Share by Players (%), 2005
Figure 5-12: US - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
Figure 5-13: US - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 5-14: US - Insulin Market (in Billion US$), 2003-2006E
Figure 5-15: US - Insulin Market Share by Players (%), 2005
Figure 5-16: Russia - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
Figure 5-17: Russia - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 5-18: Russia - Insulin Market (in Million US$), 2005-2008E
Figure 5-19: Russia - Insulin Market Share of Players (%), 2005
Figure 5-20: Russia - Insulin Market by Sales Channels (%), 2005
Figure 5-21: Japan - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
Figure 5-22: Japan - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 5-23: Japan - Insulin Market (in Million US$), 2005-2008E
Figure 5-24: Japan - Insulin Market Share of Players (%), 2006
Figure 5-25: Germany - Number of Diagnosed Diabetes Patients (in ‘000), 2003-2006E
Figure 5-26: Germany - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 5-27: Germany - Insulin Market (in Billion US$), 2004-2007E
Figure 5-28: Pakistan - Number of Diagnosed Diabetes Patients (in '000), 2003-2006E
Figure 5-29: Pakistan - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 5-30: Brazil - Number of Diagnosed Diabetes Patients (in ‘000), 2003-2006E
Figure 5-31: Brazil - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 5-32: Brazil - Insulin Market (in Million US$), 2000, 2003, 2007E & 2010E
Figure 5-33: Mexico - Number of Diagnosed Diabetes Patients (in ‘000), 2003-2006E
Figure 5-34: Mexico - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 5-35: Egypt - Number of Diagnosed Diabetes Patients (in ‘000), 2003-2006E
Figure 5-36: Egypt - Forecast for Number of Diagnosed Diabetes Patients (in '000), 2007, 2013, 2019 & 2025
Figure 6-1: US - Insulin Syringes Market (in Million US$), 2003-2006E
Figure 6-2: US - Market Share of Insulin Syringes (%), 2003-2006E
Figure 6-3: US - Forecast for Insulin Syringes Market (in Million US$), 2007-2010
Figure 6-4: US - Forecast for Market Share of Insulin Syringes (%), 2007-2010
Figure 6-5: US, Europe & Japan - Percentage of Insulin Users using Pen Devices (2003-2006E)
Figure 6-6: US - Insulin Pen Devices Market (in Million US$), 2003-2006E
Figure 6-7: Worldwide - Insulin Pen Market Shares of Key Players (%), 2006
Figure 6-8: US - Forecast for Pen Devices Market (in Million US$), 2007-2010
Figure 6-9: US - Forecast for Market Share of Insulin Pen (%), 2007-2010
Figure 6-10: Worldwide - Jet Injectors Market (in Million US$), 2003-2006E
Figure 6-11: US - Insulin driven Jet Injectors Market (in Million US$), 2003-2006E
Figure 6-12: US - Market Share of Insulin driven Jet Injectors (%), 2003-2006E
Figure 6-13: Worldwide - Forecast for Insulin Delivery Jet Injectors Market (in Million US$), 2007-2010
Figure 6-14: US - Forecast for Insulin Delivery Jet Injectors Market (in Million US$), 2007-2010
Figure 6-15: US - Forecast for Market Share of Insulin Driven Jet Injectors (%), 2007-2010
Figure 6-16: Worldwide - Insulin Pump Market (in Billion US$), 2005 & 2006E
Figure 6-17: US - Insulin Pump Market (in Million US$), 2003-2006E
Figure 6-18: Worldwide - Forecast for Insulin Pump Market (in Million US$), 2007-2010
Figure 6-19: US - Forecast for Insulin Pump Market (in Million US$), 2007 & 2008
Figure 6-20: Worldwide - Forecast for Market Share of Inhaled Insulin Devices (%), 2015
Figure 7-1: Worldwide - Forecast for Number of Diabetes Patients (in Million), 2007, 2013, 2019, 2025
Figure 7-2: Worldwide - Forecast for Diabetes Drug Market (in Billion US$), 2007-2012
Figure 7-3: Worldwide - Forecast for Insulin Market (in Billion US$), 2007-2010
Figure 7-4: Worldwide - Forecast for Insulin Demand (in Kg), 2006-2010

List of Tables:

Table 3-1: Worldwide - Top 10 Countries with Maximum Diabetic Population in Age Group 20-79 (in Million) 2003 & 2025E
Table 4-1: Worldwide - Percentage of Overweight Population (2006) & Diabetic Population by Leading Countries (2003)
Table 5-1: List of Top 10 Anti-diabetic Brands, 2005
Table 5-2: India - Diabetic Patients in Age Group 20-79 (in ‘000), 2003
Table 5-3: India - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
Table 5-4: China - Diabetic Patients in Age Group 20-79 (in ‘000), 2003
Table 5-5: China - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
Table 5-6: US - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-7: US - Forecast for Diabetic Patients in Age Group 20-79 (in ‘000), 2025
Table 5-8: Russia - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-9: Russia - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
Table 5-10: Japan - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-11: Japan - Forecast for Diabetic Patients in 20-79 Age Group (in '000), 2025
Table 5-12: Germany - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-13: Germany - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
Table 5-14: Pakistan - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-15: Pakistan - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
Table 5-16: Brazil - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-17: Brazil - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
Table 5-18: Mexico - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-19: Mexico - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
Table 5-20: Egypt - Diabetic Patients in Age Group 20-79 (in '000), 2003
Table 5-21: Egypt - Forecast for Diabetic Patients in Age Group 20-79 (in '000), 2025
Table 8-1: Eli Lilly & Company - Key Financials (in Million US$), 2004-2006
Table 8-2: Novo Nordisk A/S - Key Financials (in Million US$), 2004-2006
Table 8-3: Sanofi-Aventis - Key Financials (in Million US$), 2003-2005
Table 8-4: GlaxoSmithKline - Key Financials (in Million US$), 2004-2006
Table 8-5: Amylin Pharmaceuticals, Inc. - Key Financials (in Million US$), 2004-2006

For full details, please email keithw@cmsinfo.com

Top of Page

Buy now!

Single user PDF

 GBP 921.05   

Multi-User License

 GBP 1315.79   

Hard copy

 GBP 1118.42   

CD-Rom

 GBP 1118.42   

Your personal guarantee

Top of Page